After long-term use of lorlatinib/lorlatinib, can it be safely discontinued?

Lorlatinib (Lorlatinib), also known as lorlatinib, is a third-generation highly effective inhibitor of ALK and ROS1. It was developed specifically to solve the problem of drug-resistant ALK mutations caused by first- or second-generation ALK TKIs. In early-stage clinical trials involving adult patients with ALK- or ROS1-driven NSCLC, lorlatinib monotherapy demonstrated significant and durable efficacy, even in patients with central nervous system (CNS) metastases or who had previously received other ALK TKIs.

For those patients who have been taking lorlatinib for a long time, the decision to discontinue the drug is not straightforward. Although long-term medication may bring stable efficacy, it may also be accompanied by side effects and drug resistance issues. Therefore, whether to discontinue medication requires a comprehensive assessment of the patient's specific condition, including the stability of the condition, the effectiveness of previous treatments, the severity of side effects, and overall health.

When doctors evaluate the feasibility of discontinuing medication, they will pay special attention to whether the patient's condition is stable and whether there is a risk of recurrence. If the condition is well controlled and there are no obvious signs of recurrence, the doctor may consider gradually reducing the dosage of the drug or stopping the drug completely. However, if the disease is still active or there is a high risk of recurrence, the doctor may recommend continuing treatment or adjusting the treatment plan.

The patient's personal feelings and needs also play an important role in discontinuation decisions. If side effects caused by long-term medication, such as nausea, vomiting, fatigue, etc., have seriously affected the quality of life, patients should actively communicate with their doctors to discuss whether it is appropriate to discontinue the medication or adjust treatment strategies.

Additionally, the body's tolerance for the medication needs to be considered. Long-term use of lorlatinib may cause the body to gradually develop drug resistance, thereby reducing the effectiveness of the drug. In this case, your doctor may recommend switching to other medications or a new treatment strategy.